NuCana BioMed
NuCana BioMed, a biopharmaceutical company, develops and commercializes rationally designed medicines for significant unmet medical needs.
Business Model:
Revenue: $0
Employees: 11-50
Rankings
Industries / Tags:
Detailed NuCana BioMed Information
Geographic Data
Address:
City: Edinburgh
State: Edinburgh, City of
Zip:
Country: United Kingdom
Financial Info
Stage:
post ipo equity
Raised Last:
$80M
Raised Total:$248M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
NuCana BioMed is an emerging biopharmaceutical company dedicated to the discovery, development and commercialisation of innovative, rationally designed medicines that address significant unmet medical needs. Our management team has extensive experience of building successful biopharmaceutical companies. This includes the formation and subsequent growth of Bioenvision into a NASDAQ National listed, global biopharmaceutical company, which was acquired by Genzyme Corporation in October 2007. Specific management expertise includes the development, approval and commercialisation of oncology medicines. We are developing a portfolio of first-in-class and best-in-class pharmaceutical products designed to treat life-threatening or debilitating diseases. Our primary focus is in the area of oncology, although our technology platform has broader clinical potential.
Contact Phone:
Contact Email:
NuCana BioMed went public on 9/27/2017 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
9/27/2017
IPO Valuation:
$463M
Ticker Symbol:
NCNA
IPO Price:
$15/share
Amount Raised:
$100M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 9/2017 | Post-IPO Equity | $100M | 11/2011 | Series A | 3 | $10.5M |
Morningside Group Scottish Enterprise Sofinnova Partners Morningside Group Scottish Enterprise Sofinnova Partners |
4/2014 | Series B | 2 | $57M |
Scottish Investment Bank Sofinnova Investments Scottish Investment Bank Sofinnova Investments |
10/2020 | Post-IPO Equity | 1 | $80M |
Abingworth Abingworth |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
